irinotecan has been researched along with Leukemia, Pre-B-Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, H; Miyashita, T; Takemura, H; Ueda, T; Yoshida, A | 1 |
1 other study(ies) available for irinotecan and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Buthionine Sulfoximine; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Death; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Gene Expression Regulation, Leukemic; Glutathione; Humans; Irinotecan; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2006 |